Can ENHANCE Diminish Vytorin? Schering, Merck Minimize Trial’s Importance
Executive Summary
Schering-Plough and Merck are downplaying the significance of upcoming results from the ENHANCE trial comparing Vytorin (ezetimibe/simvastatin) to simvastatin alone in inhibiting atherosclerosis of the carotid artery
You may also be interested in...
UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009
National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs
UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009
National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.